Covered recipient · General Payments record
MOSAB R DEEN
Allopathic & Osteopathic Physicians General Practice
General Payments · PY2018–2023
$30,555.75
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $29,105.00 | 14 |
| Travel and Lodging | $741.57 | 1 |
| Food and Beverage | $543.53 | 2 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| CSL Plasma Inc. | $29,105.00 | 14 |
| Neuronetics, Inc. | $1,285.10 | 3 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| CSL Plasma Inc. | $125.00 | 02/08/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370923 | CMS |
| CSL Plasma Inc. | $285.80 | 02/14/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370925 | CMS |
| CSL Plasma Inc. | $1,864.80 | 02/14/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370927 | CMS |
| CSL Plasma Inc. | $3,686.40 | 02/23/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370929 | CMS |
| CSL Plasma Inc. | $3,386.40 | 03/08/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370931 | CMS |
| CSL Plasma Inc. | $2,464.80 | 03/15/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370933 | CMS |
| CSL Plasma Inc. | $3,872.40 | 03/21/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370935 | CMS |
| CSL Plasma Inc. | $3,686.40 | 04/05/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370937 | CMS |
| CSL Plasma Inc. | $1,117.00 | 04/05/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370939 | CMS |
| CSL Plasma Inc. | $2,454.00 | 04/26/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370941 | CMS |
| CSL Plasma Inc. | $1,227.00 | 04/26/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370943 | CMS |
| CSL Plasma Inc. | $2,154.00 | 05/04/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051370945 | CMS |
| CSL Plasma Inc. | $927.00 | 05/04/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051371119 | CMS |
| CSL Plasma Inc. | $1,854.00 | 05/18/2023 | Consulting Fee | Undisputed | 01/23/2026 | 1051371121 | CMS |
| Neuronetics, Inc. | $31.32 | 07/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | 966807745 | CMS |
| Neuronetics, Inc. | $512.21 | 09/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1017934341 | CMS |
| Neuronetics, Inc. | $741.57 | 09/06/2023 | Travel and Lodging | Undisputed | 01/23/2026 | 1017934643 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2023
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.